Remove tag
article thumbnail

Can gene therapies for haemophilia defend their high price tags?

Pharmaceutical Technology

CSL Behring has a commercialisation and license agreement to develop EtranaDez. million price tag. The post Can gene therapies for haemophilia defend their high price tags? A fair price for CSL Behring’s haemophilia B treatment etranacogene dezaparvovec would be between $2.93–2.96 million ($1.8 million at the time).

article thumbnail

FDA gives Daiichi Sankyo’s HER3 drug a breakthrough tag

pharmaphorum

AZ has already licensed rights to HER2-targeting drug Enhertu (trastuzumab deruxtecan) – which is already on the market for HER2-positive breast and gastric cancers – as well as investigational TROP2 ADC datopotamab deruxtecan in two multibillion-dollar deals. Daiichi Sankyo and AZ are close collaborators in the ADC arena.

Drugs 72
Insiders

Sign Up for our Newsletter

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

article thumbnail

Enhertu gets breakthrough tag in HER2-low breast cancer

pharmaphorum

billion upfront to license rights to the drug in a deal that could be worth up to $6.9 The post Enhertu gets breakthrough tag in HER2-low breast cancer appeared first on.

Sales 59
article thumbnail

First gene therapy for haemophilia B gets go ahead in Europe

Drug Discovery World

The clinical development of etranacogene dezaparvovec was led by uniQure and sponsorship of the clinical trials transitioned to CSL after it licensed global rights to commercialise the treatment. . World’s most expensive drug. A one-time treatment with etranacogene dezaparvovec costs US$3.5

article thumbnail

Upcoming sickle cell gene therapies cost effective at $2 million, says ICER

Pharmaceutical Technology

Although the findings in the report are only preliminary, they shed light at the considerations behind the high price tags of gene therapies. While Vertex and CRISPR submitted the Biologics License Application (BLA) for exa-cel earlier this April, bluebird has yet to do so for lovo-cel.

article thumbnail

Grand Rounds June 30, 2023: Decentralized Trials – From Guidance to Reality & What’s Left (Adrian Hernandez, MD, MHS; Pamela Tenaerts, MD, MPH; Craig Lipset, MPH)

Rethinking Clinical Trials

Interstate licensing and our own institution’s policies are issues that still need to be addressed in terms of oversight and responsibilities. The idea that health care providers in our communities may have data about an adverse event is not necessarily new, and health care providers are often aware of an adverse event very early on.

Trials 130
article thumbnail

Further insight into breakthroughs in mRNA drug discovery 

Drug Discovery World

We have shown that the excipient does not only work for our SNAP-tag lipid (SNaP) LNP, but also for the commercialised vaccines. The excipient is listed in the pharmacopoeia as an inactive ingredient and therefore can easily added to an existing formulation.

Drugs 52